Corporate Member News

October 1, 2021

G1 Therapeutics J-Code Announcement

G1 Therapeutics, Inc. secures permanent J Code for COSELA™ (trilaciclib). The code, J1448, is effective on October 1, 2021. Visit for more information.
September 30, 2021

CASPIAN 3-Year Data for IMFINZI® (durvalumab)

We are pleased to inform you that there are new data available for IMFINZI® (durvalumab) from the CASPIAN trial’s 3-year planned exploratory analysis, including overall survival […]